Long-term evaluation of advanced Parkinson’s disease burden and clinical outcomes: results from the PROSPECT observational study
Objective: Evaluate long-term clinical outcomes and disease burden in people with advanced Parkinson's disease (PwP) with motor fluctuations not optimized by their current medications. Background:…Characterization of Infusion Site Reactions With 24-hour Subcutaneous Infusion of ND0612
Objective: To characterize infusion site reactions (ISRs) reported as adverse events (AEs) in clinical studies of ND0612. Background: ND0612 is an investigational, subcutaneous infusion of…Effect of Opicapone and Levodopa on the Different Daily OFF Patterns in Patients with Parkinson’s Disease and Early Motor Fluctuations: Findings from the Korean ADOPTION Study
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus an additional 100 mg levodopa (L-DOPA) dose on the different daily OFF patterns in…Assessing a Video Based Approach at Measuring Parkinson’s Disease Severity – A Validation Study
Objective: To validate the Parkinson’s remote interactive monitoring system’s assessment of Parkinson’s disease compared to a clinical assessment completed by a movement disorder specialist. Background:…Remote recruitment of hyposmic participants identifies biomarkers related to neuronal alpha-synuclein disease
Objective: To evaluate the proportion of people with dopaminergic deficit and positive alpha-synuclein seed amplification assay (aSyn SAA) among a remotely identified group of hyposmic…Safety and tolerability of opicapone in Parkinson’s Disease: from early-stage (EPSILON study) to late-stage (BIPARK studies)
Objective: To compare the safety and tolerability of once-daily opicapone (OPC) 50mg as add-on to stable levodopa/dopa decarboxylase inhibitor (L-DOPA/DDCI) therapy in patients from early…Remotely-deployed gamification intervention to increase physical activity in Parkinson’s Disease
Objective: To describe a remote, behavioral intervention designed to increase daily steps in Veterans with PD and report interim results from an ongoing clinical trial…First-In-Human Single and Multiple Ascending Dose Trial Design of LY3962681, a Novel Intrathecally Delivered siRNA Targeting α-synuclein mRNA for the Treatment of Patients with Parkinson’s Disease
Objective: Development of a Phase 1 clinical trial evaluating LY3962681, a novel, intrathecally delivered siRNA directly targeting α-synucleinmRNA (SNCA) to reduce α-synuclein protein (ASYN), for the treatment of…Efficacy of Novel A2A/A1 Antagonist in Motor and non-Motor Symptoms of MPTP-Treated Macaques
Objective: Our primary objective was to test the novel adenosine A2A/A1 receptor antagonist IDAA-338 in alleviating Parkinsonian symptoms when given as a mono or as…Formulations and Assessments of Intra-nasal noses to brain curcumin delivery using reversible nanoparticles for Parkinsonism treatment: A Preclinical Approach
Objective: Parkinson's disease (PD) is a prevalent neurological illness that is typified by bradykinesia, postural instability, tremor, and stiffness. An increasing body of research suggests…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.